Eplerenone + Placebo or sugar pill
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ischemic Heart Disease
Conditions
Ischemic Heart Disease
Trial Timeline
Aug 1, 2004 → Dec 1, 2011
NCT ID
NCT00187889About Eplerenone + Placebo or sugar pill
Eplerenone + Placebo or sugar pill is a approved stage product being developed by Pfizer for Ischemic Heart Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00187889. Target conditions include Ischemic Heart Disease.
What happened to similar drugs?
9 of 13 similar drugs in Ischemic Heart Disease were approved
Approved (9) Terminated (3) Active (4)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00187889 | Approved | Completed |
Competing Products
20 competing products in Ischemic Heart Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Aspirin, Clopidogrel | Yuhan | Pre-clinical | 26 |
| DS-1040b + Placebo | Daiichi Sankyo | Phase 1/2 | 32 |
| DS-1040b + Aspirin | Daiichi Sankyo | Phase 1 | 29 |
| DS1040b + Placebo | Daiichi Sankyo | Pre-clinical | 26 |
| Pharmacological intensification based on olmesartan | Daiichi Sankyo | Phase 2 | 35 |
| Regadenoson | Astellas Pharma | Phase 1 | 29 |
| YM872 (zonampanel), t-PA (alteplase) | Astellas Pharma | Phase 2 | 35 |
| Regadenoson | Astellas Pharma | Approved | 43 |
| ASP2246 | Astellas Pharma | Phase 1/2 | 39 |
| Gadolinium + Adenosine | Astellas Pharma | Phase 2/3 | 38 |
| XY03-EA + XY03-EA Placebo | Sun Pharmaceutical | Phase 2 | 31 |
| Redasemtide + Placebo | Shionogi | Phase 2 | 39 |
| Statin | Shionogi | Approved | 43 |
| fospropofol + propofol | Eisai | Phase 2 | 35 |
| PDE5 Inhibitors | Eli Lilly | Pre-clinical | 26 |
| SB623 Implant (2.5M) + SB623 Implant (5.0M) | Sumitomo Pharma | Phase 2 | 35 |
| Mesenchymal stem cell + Placebo | Rohto Pharmaceutical | Phase 2 | 42 |
| Elezanumab + Placebo | AbbVie | Phase 2 | 35 |
| Balovaptan + Placebo | Roche | Phase 2 | 27 |
| Repatha | Amgen | Approved | 35 |